Phenotype-specific treatment of heart failure with preserved ejection fraction

Circulation

Volumn 134, Issue 1, 2016, Pages 73-90

  Shah, Sanjiv J ^a   Kitzman, Dalane W ^b   Borlaug, Barry A ^c   Van Heerebeek, Loek ^d,e   Zile, Michael R ^f   Kass, David A ^g   Paulus, Walter J ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

diastole; heart failure; heart failure, diastolic; phenotype; therapeutics; ventricular function, left

Indexed keywords

CYCLIC GMP; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; NITRATE; NITRIC OXIDE; NITRITE; PHOSPHODIESTERASE V INHIBITOR; SACUBITRIL; SPIRONOLACTONE;

ARTICLE; ATRIAL FIBRILLATION; CALORIC RESTRICTION; CHRONOTROPISM; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; EXERCISE; FIBROSING ALVEOLITIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FAILURE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LUNG; LUNG CONGESTION; MUSCLE WEAKNESS; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SKELETAL MUSCLE; SODIUM RETENTION; COMPLICATION; FEMALE; HEART FAILURE; HEART STROKE VOLUME; INFLAMMATION; KIDNEY DISEASE; MALE; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

COMBINED MODALITY THERAPY; COMORBIDITY; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; INFLAMMATION; KIDNEY DISEASES; MALE; MUSCLE WEAKNESS; PHENOTYPE; PRECISION MEDICINE; SIGNAL TRANSDUCTION; STROKE VOLUME;

EID: 84977271048     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.021884     Document Type: Article

References (155)

1. Borlaug BA, Baliga RR, Haas GJ, Heart failure with preserved ejection fraction. Management of Heart Failure 2015 New York, NY Springer Verlag 213 230
2. Paulus WJ, van Ballegoij JJ, Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010 55 526 537. doi: 10.1016/j.jacc.2009.06.067.
3. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH, Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-Analysis. J Am Coll Cardiol 2011 57 1676 1686. doi: 10.1016/j.jacc.2010.10.057.
4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 362 777 781. doi: 10.1016/S0140-6736(03)14285-7.
5. Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE, Prognostic value of baseline plasma amino-Terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 2011 4 569 577. doi: 10.1161/CIRCHEARTFAILURE.111.962654.
6. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA, TOPCAT Investigators Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016 37 455 462. doi: 10.1093/eurheartj/ehv464.
7. Sanderson JE, Heart failure with a normal ejection fraction. Heart 2007 93 155 158. doi: 10.1136/hrt.2005.074187.
8. De Keulenaer GW, Brutsaert DL, Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 2011 123 1996 2004. discussion 2005. doi: 10.1161/CIRCULATIONAHA.110.981431.
9. Packer M, Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail 2011 4 538 540. doi: 10.1161/CIRCHEARTFAILURE.111.963710.
10. Paulus WJ, Tschöpe C, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013 62 263 271. doi: 10.1016/j.jacc.2013.02.092.
11. Shah AM, Solomon SD, Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. Eur Heart J 2012 33 1716 1717. doi: 10.1093/eurheartj/ehs124.
12. Shah AM, Pfeffer MA, The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol 2012 9 555 556. doi: 10.1038/nrcardio.2012.123.
13. Shah SJ, Katz DH, Deo RC, Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin 2014 10 407 418. doi: 10.1016/j.hfc.2014.04.008.
14. Ferrari R, Böhm M, Cleland JG, Paulus WJ, Pieske B, Rapezzi C, Tavazzi L, Heart failure with preserved ejection fraction: uncertainties and dilemmas. Eur J Heart Fail 2015 17 665 671. doi: 10.1002/ejhf.304.
15. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE, Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011 4 324 331. doi: 10.1161/CIRCHEARTFAILURE.110.959890.
16. Dhingra A, Garg A, Kaur S, Chopra S, Batra JS, Pandey A, Chaanine AH, Agarwal SK, Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2014 11 354 365. doi: 10.1007/s11897-014-0223-7.
17. Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS, Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-Terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012 14 1338 1347. doi: 10.1093/eurjhf/hfs130.
18. Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, Boersma E, Kardys I, Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail 2013 15 1350 1362. doi: 10.1093/eurjhf/hft106.
19. Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF investigators Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 2015 17 1006 1014. doi: 10.1002/ejhf.414.
20. D'Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M, Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail 2015 17 1231 1239. doi: 10.1002/ejhf.430.
21. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N, Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2016 4 312 314. doi: 10.1016/j.jchf.2015.10.007.
22. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschöpe C, Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011 4 44 52. doi: 10.1161/CIRCHEARTFAILURE.109.931451.
23. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ, Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012 126 830 839. doi: 10.1161/CIRCULATIONAHA.111.076075.
24. LeWinter MM, Granzier HL, Cardiac titin and heart disease. J Cardiovasc Pharmacol 2014 63 207 212. doi: 10.1097/FJC.0000000000000007.
25. Linke WA, Hamdani N, Gigantic business: titin properties and function through thick and thin. Circ Res 2014 114 1052 1068. doi: 10.1161/CIRCRESAHA.114.301286.
26. Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, Sinha M, Dall'Osso C, Khong D, Shadrach JL, Miller CM, Singer BS, Stewart A, Psychogios N, Gerszten RE, Hartigan AJ, Kim MJ, Serwold T, Wagers AJ, Lee RT, Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013 153 828 839. doi: 10.1016/j.cell.2013.04.015.
27. González A, Ravassa S, Beaumont J, López B, Díez J, New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011 58 1833 1843. doi: 10.1016/j.jacc.2011.06.058.
28. de Denus S, Lavoie J, Ducharme A, O'Meara E, Racine N, Sirois MG, Neagoe PE, Zhu L, Rouleau JL, White M, Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol 2012 28 62 68. doi: 10.1016/j.cjca.2011.09.007.
29. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL, B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013 61 1498 1506. doi: 10.1016/j.jacc.2012.12.044.
30. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, Borlaug BA, McNulty S, Hernandez AF, Braunwald E, Redfield MM, Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J 2012 164 763 770.e3. doi: 10.1016/j.ahj.2012.08.014.
31. Gaasch WH, Zile MR, Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011 58 1733 1740. doi: 10.1016/j.jacc.2011.07.022.
32. Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, Khera A, McGuire DK, Vega GL, de Lemos JA, Turer AT, Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol 2013 62 752 760. doi: 10.1016/j.jacc.2013.03.038.
33. Paulus WJ, Culprit Mechanism(s) for Exercise Intolerance in Heart Failure With Normal Ejection Fraction. J Am Coll Cardiol 2010 56 864 866. doi: 10.1016/j.jacc.2010.04.041.
34. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM, Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010 56 845 854. doi: 10.1016/j.jacc.2010.03.077.
35. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM, Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. J Am Coll Cardiol 2010 56 855 863. doi: 10.1016/j.jacc.2010.04.040.
36. Andersen MJ, Olson TP, Melenovsky V, Kane GC, Borlaug BA, Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure. Circ Heart Fail 2015 8 41 48. doi: 10.1161/CIRCHEARTFAILURE.114.001731.
37. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM, Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010 3 588 595. doi: 10.1161/CIRCHEARTFAILURE.109.930701.
38. Borlaug BA, Jaber WA, Ommen SR, Lam CS, Redfield MM, Nishimura RA, Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011 97 964 969. doi: 10.1136/hrt.2010.212787.
39. Santos M, Opotowsky AR, Shah AM, Tracy J, Waxman AB, Systrom DM, Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction. Circ Heart Fail 2015 8 278 285. doi: 10.1161/CIRCHEARTFAILURE.114.001551.
40. Dhakal BP, Malhotra R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD, Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015 8 286 294. doi: 10.1161/CIRCHEARTFAILURE.114.001825.
41. van Empel VP, Mariani J, Borlaug BA, Kaye DM, Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc 2014 3 e001293. doi: 10.1161/JAHA.114.001293.
42. Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW, Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 2011 58 265 274. doi: 10.1016/j.jacc.2011.02.055.
43. Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW, Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci 2013 68 968 975. doi: 10.1093/gerona/glt011.
44. Cowley AW Jr, Abe M, Mori T, O'Connor PM, Ohsaki Y, Zheleznova NN, Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertension. Am J Physiol Renal Physiol 2015 308 F179 F197. doi: 10.1152/ajprenal.00455.2014.
45. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC, Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008 118 1433 1441. doi: 10.1161/CIRCULATIONAHA.108.783910.
46. Maisel AS, Shah KS, Barnard D, Jaski B, Frivold G, Marais J, Azer M, Miyamoto MI, Lombardo D, Kelsay D, Iqbal N, Taub PR, Kupfer K, Lee E, Clopton P, Zile M, Greenberg B, How B-Type natriuretic peptide (BNP) and body weight changes vary in heart failure with preserved ejection fraction compared with reduced ejection fraction: secondary results of the HABIT (HF Assessment With BNP in the Home) Trial. J Card Fail 2016 22 283 293. doi: 10.1016/j.cardfail.2015.09.014.
47. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM, New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014 35 2797 2815. doi: 10.1093/eurheartj/ehu204.
48. Sharma K, Kass DA, Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014 115 79 96. doi: 10.1161/CIRCRESAHA.115.302922.
49. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC, Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015 131 269 279. doi: 10.1161/CIRCULATIONAHA.114.010637.
50. Deo RC, Machine learning in medicine. Circulation 2015 132 1920 30. doi: 10.1161/CIRCULATIONAHA.115.001593.
51. Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, Rodeheffer RJ, Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 2013 6 944 952. doi: 10.1161/CIRCHEARTFAILURE.113.000383.
52. Wohlfahrt P, Redfield MM, Lopez-Jimenez F, Melenovsky V, Kane GC, Rodeheffer RJ, Borlaug BA, Impact of general and central adiposity on ventricular-Arterial aging in women and men. JACC Heart Fail 2014 2 489 499. doi: 10.1016/j.jchf.2014.03.014.
53. Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S, ALLHAT Collaborative Research Group Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008 118 2259 2267. doi: 10.1161/CIRCULATIONAHA.107.762229.
54. Borlaug BA, The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014 11 507 515. doi: 10.1038/nrcardio.2014.83.
55. van Dijk CG, Oosterhuis NR, Xu YJ, Brandt M, Paulus WJ, van Heerebeek L, Duncker DJ, Verhaar MC, Fontoura D, Lourenço AP, Leite-Moreira AF, Falcão-Pires I, Joles JA, Cheng C, Distinct endothelial cell responses in the heart and kidney microvasculature characterize the progression of heart failure with preserved ejection fraction in the obese ZSF1 rat with cardiorenal metabolic syndrome. Circ Heart Fail 2016 9 e002760. doi: 10.1161/CIRCHEARTFAILURE.115.002760.
56. Zile MR, Sharma V, Johnson JW, Warman EN, Baicu CF, Bennett TD, Prediction of all-cause mortality based on the direct measurement of intrathoracic impedance. Circ Heart Fail 2016 9 e002543. doi: 10.1161/CIRCHEARTFAILURE.115.002543.
57. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, Henderson J, Cowart P, Stevenson LW, Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 2014 7 935 944. doi: 10.1161/CIRCHEARTFAILURE.113.001229.
58. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, CHAMPION Trial Study Group Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016 387 453 461. doi: 10.1016/S0140-6736(15)00723-0.
59. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, Eggebeen J, Nicklas BJ, Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2016 315 36 46. doi: 10.1001/jama.2015.17346.
60. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL, Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008 51 415 426. doi: 10.1016/j.jacc.2007.10.009.
61. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM, Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011 124 335 345. doi: 10.1161/CIRCULATIONAHA.110.985150.
62. Zakeri R, Chamberlain AM, Roger VL, Redfield MM, Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013 128 1085 1093. doi: 10.1161/CIRCULATIONAHA.113.001475.
63. Fukuta H, Sane DC, Brucks S, Little WC, Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005 112 357 363. doi: 10.1161/CIRCULATIONAHA.104.519876.
64. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H, CHART-2 Investigators Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 2015 79 574 582. doi: 10.1253/circj.CJ-14-0865.
65. Alehagen U, Benson L, Edner M, Dahlström U, Lund LH, Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50. Circ Heart Fail 2015 8 862 870. doi: 10.1161/CIRCHEARTFAILURE.115.002143.
66. Gomberg-Maitland M, Shah SJ, Guazzi M, Inflammation in heart failure with preserved ejection fraction: time to put out the fire. JACC Heart Fail 2016 4 325 328. doi: 10.1016/j.jchf.2015.11.013.
67. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E, NHLBI Heart Failure Clinical Research Network Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 2015 373 2314 2324. doi: 10.1056/NEJMoa1510774.
68. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA, Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012 59 442 451. doi: 10.1016/j.jacc.2011.09.062.
69. Thomas GR, DiFabio JM, Gori T, Parker JD, Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007 49 1289 1295. doi: 10.1016/j.jacc.2006.10.074.
70. Oelze M, Knorr M, Kröller-Schön S, Kossmann S, Gottschlich A, Rümmler R, Schuff A, Daub S, Doppler C, Kleinert H, Gori T, Daiber A, Münzel T, Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J 2013 34 3206 3216. doi: 10.1093/eurheartj/ehs100.
71. Vanderpool R, Gladwin MT, Harnessing the nitrate-nitrite-nitric oxide pathway for therapy of heart failure with preserved ejection fraction. Circulation 2015 131 334 336. doi: 10.1161/CIRCULATIONAHA.114.014149.
72. Omar SA, Fok H, Tilgner KD, Nair A, Hunt J, Jiang B, Taylor P, Chowienczyk P, Webb AJ, Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation 2015 131 381 389. discussion 389. doi: 10.1161/CIRCULATIONAHA.114.009554.
73. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA, Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 2015 131 371 380. discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957.
74. Borlaug BA, Koepp KE, Melenovsky V, Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2015 66 1672 1682. doi: 10.1016/j.jacc.2015.07.067.
75. Eggebeen J, Kim-Shapiro DB, Haykowsky M, Morgan TM, Basu S, Brubaker P, Rejeski J, Kitzman DW, One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction (published online ahead of print February 2, 2016). JACC Heart Fail. doi: 10.1016/j.jchf.2015.12.013. http://www.sciencedirect.com/science/article/pii/S2213177915008355
76. Blanton RM, Takimoto E, Lane AM, Aronovitz M, Piotrowski R, Karas RH, Kass DA, Mendelsohn ME, Protein kinase g i inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc 2012 1 e003731. doi: 10.1161/JAHA.112.003731.
77. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA, Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 2010 48 713 724. doi: 10.1016/j.yjmcc.2009.11.015.
78. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA, Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 2009 119 408 420. doi: 10.1172/JCI35620.
79. Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T, Koitabashi N, Barth AS, Bedja D, Gabrielson KL, Wang Y, Kass DA, Myocardial remodeling is controlled by myocyte-Targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol 2010 56 2021 2030. doi: 10.1016/j.jacc.2010.08.612.
80. Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA, Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015 519 472 476. doi: 10.1038/nature14332.
81. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA, Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005 11 214 222. doi: 10.1038/nm1175.
82. Ranek MJ, Terpstra EJ, Li J, Kass DA, Wang X, Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 2013 128 365 376. doi: 10.1161/CIRCULATIONAHA.113.001971.
83. Omori K, Kotera J, Overview of PDEs and their regulation. Circ Res 2007 100 309 327. doi: 10.1161/01.RES.0000256354.95791.f1.
84. Lee DI, Kass DA, Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology (Bethesda) 2012 27 248 258. doi: 10.1152/physiol.00011.2012.
85. Kirk JA, Holewinski RJ, Crowgey EL, Van Eyk JE, Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials. Proteomics 2016 16 894 905. doi: 10.1002/pmic.201500401.
86. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA, Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 2009 104 87 94. doi: 10.1161/CIRCRESAHA.108.184408.
87. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ, Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009 104 780 786. doi: 10.1161/CIRCRESAHA.108.193326.
88. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA, Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res 2013 97 464 471. doi: 10.1093/cvr/cvs353.
89. Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J, Chen YF, ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985) 2007 102 390 398. doi: 10.1152/japplphysiol.00468.2006.
90. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, COMPOSE Investigators and Coordinators Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012 14 1056 1066. doi: 10.1093/eurjhf/hfs093.
91. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, PATENT-1 Study Group Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013 369 330 340. doi: 10.1056/NEJMoa1209655.
92. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C, CHEST-1 Study Group Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013 369 319 329. doi: 10.1056/NEJMoa1209657.
93. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, Semigran MJ, Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013 128 502 511. doi: 10.1161/CIRCULATIONAHA.113.001458.
94. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B, SOCRATES-REDUCED Investigators and Coordinators Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED Randomized Trial. JAMA 2015 314 2251 2262. doi: 10.1001/jama.2015.15734.
95. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012 380 1387 1395. doi: 10.1016/S0140-6736(12)61227-6.
96. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch KD, Janssens SP, Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009 119 408 416. doi: 10.1161/CIRCULATIONAHA.108.822072.
97. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB, Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 2012 5 79 86. doi: 10.1161/CIRCHEARTFAILURE.111.961706.
98. Degen CV, Bishu K, Zakeri R, Ogut O, Redfield MM, Brozovich FV, The emperor's new clothes: PDE5 and the heart. PLoS One 2015 10 e0118664. doi: 10.1371/journal.pone.0118664.
99. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013 309 1268 1277. doi: 10.1001/jama.2013.2024.
100. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA, Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015 36 2565 2573. doi: 10.1093/eurheartj/ehv336.
101. Kroker KS, Mathis C, Marti A, Cassel JC, Rosenbrock H, Dorner-Ciossek C, PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 2014 35 2072 2078. doi: 10.1016/j.neurobiolaging.2014.03.023.
102. Spinale FG, Zile MR, Integrating the myocardial matrix into heart failure recognition and management. Circ Res 2013 113 725 738. doi: 10.1161/CIRCRESAHA.113.300309.
103. López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J, Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol 2016 67 251 260. doi: 10.1016/j.jacc.2015.10.063
104. Moore-Morris T, Cattaneo P, Puceat M, Evans SM, Origins of cardiac fibroblasts. J Mol Cell Cardiol 2016 91 1 5. doi: 10.1016/j.yjmcc.2015.12.031.
105. Moore-Morris T, Guimarães-Camboa N, Banerjee I, Zambon AC, Kisseleva T, Velayoudon A, Stallcup WB, Gu Y, Dalton ND, Cedenilla M, Gomez-Amaro R, Zhou B, Brenner DA, Peterson KL, Chen J, Evans SM, Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J Clin Invest 2014 124 2921 2934. doi: 10.1172/JCI74783.
106. Baicu CF, Zhang Y, Van Laer AO, Renaud L, Zile MR, Bradshaw AD, Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol 2012 303 H234 H240. doi: 10.1152/ajpheart.00227.2012.
107. Spinale FG, Janicki JS, Zile MR, Membrane-Associated matrix proteolysis and heart failure. Circ Res 2013 112 195 208. doi: 10.1161/CIRCRESAHA.112.266882.
108. Zile MR, Baicu CF, Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 2013 6 501 515. doi: 10.1007/s12265-013-9472-1.
109. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 370 1383 1392. doi: 10.1056/NEJMoa1313731.
110. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015 131 34 42. doi: 10.1161/CIRCULATIONAHA.114.013255.
111. Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD, Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail 2016 9 e002551. doi: 10.1161/CIRCHEARTFAILURE.115.002551.
112. López B, Querejeta R, González A, Beaumont J, Larman M, Díez J, Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009 53 236 242. doi: 10.1161/HYPERTENSIONAHA.108.125278.
113. Gallet R, de Couto G, Simsolo E, Valle J, Sun B, Liu W, Tseliou E, Zile MR, Marbán E, Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. JACC Basic Transl Sci 2016 1 14 28. doi: 10.1016/j.jacbts.2016.01.003.
114. Borlaug BA, Lewis GD, McNulty SE, Semigran MJ, LeWinter M, Chen H, Lin G, Deswal A, Margulies KB, Redfield MM, Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail 2015 8 533 541. doi: 10.1161/CIRCHEARTFAILURE.114.001915.
115. Rodríguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ, The immunological basis of hypertension. Am J Hypertens 2014 27 1327 1337. doi: 10.1093/ajh/hpu142.
116. Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, Weder AB, Kovács SJ, Kolias TJ, Low-sodium DASH diet improves diastolic function and ventricular-Arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 2013 6 1165 1171. doi: 10.1161/CIRCHEARTFAILURE.113.000481.
117. ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, van Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA, Connecting heart failure with preserved ejection fraction and renal dysfunction-The role of endothelial dysfunction and inflammation (published online ahead of print February 10, 2016). Eur J Heart Fail. doi: 10.1002/ejhf.497. http://onlinelibrary.wiley.com/doi/10.1002/ejhf.497/abstract;jsessionid=E19342D20449BC5FB6C4E00DBE86EE52.f04t01
118. Klein DA, Katz DH, Beussink-Nelson L, Sanchez CL, Strzelczyk TA, Shah SJ, Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. Am J Cardiol 2015 116 1093 1100. doi: 10.1016/j.amjcard.2015.06.038.
119. Damkjær M, Vafaee M, Møller ML, Braad PE, Petersen H, Høilund-Carlsen PF, Bie P, Renal cortical and medullary blood flow responses to altered NO availability in humans. Am J Physiol Regul Integr Comp Physiol 2010 299 R1449 R1455. doi: 10.1152/ajpregu.00440.2010.
120. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, Claggett B, Shah AM, Santos AB, Zile MR, Voors AA, McMurray JJ, Packer M, Bransford T, Lefkowitz M, Solomon SD, PARAMOUNT Investigators Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014 35 3442 3451. doi: 10.1093/eurheartj/ehu254.
121. Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ, Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2016 18 103 112
122. Hwang SJ, Melenovsky V, Borlaug BA, Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014 63 25 pt A 2817 2827. doi: 10.1016/j.jacc.2014.03.034.
123. Greenberg B, Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 2014 63 25 pt A 2828 2830. doi: 10.1016/j.jacc.2014.03.033.
124. Rusinaru D, Houpe D, Szymanski C, Lévy F, Maréchaux S, Tribouilloy C, Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 2014 16 967 976. doi: 10.1002/ejhf.142.
125. Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, Borlaug BA, Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013 15 776 785. doi: 10.1093/eurjhf/hft026.
126. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA, Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006 114 2138 2147. doi: 10.1161/CIRCULATIONAHA.106.632745.
127. Brubaker PH, Joo KC, Stewart KP, Fray B, Moore B, Kitzman DW, Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 2006 26 86 89
128. Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, Weaver R, Ahmed I, Frenneaux M, Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 2010 3 29 34. doi: 10.1161/CIRCHEARTFAILURE.109.877720.
129. Pal N, Sivaswamy N, Mahmod M, Yavari A, Rudd A, Singh S, Dawson DK, Francis JM, Dwight JS, Watkins H, Neubauer S, Frenneaux M, Ashrafian H, Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 2015 132 1719 1725. doi: 10.1161/CIRCULATIONAHA.115.017119.
130. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Ding YA, Lin SJ, Comparison of endothelial vasodilator function, inflammatory markers, and N-Terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart 2006 92 609 614. doi: 10.1136/hrt.2005.064147.
131. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM, Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009 53 1119 1126. doi: 10.1016/j.jacc.2008.11.051.
132. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA, Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014 35 3452 3462. doi: 10.1093/eurheartj/ehu193.
133. Mohammed SF, Hussain I, AbouEzzeddine OF, Abou Ezzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM, Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014 130 2310 2320. doi: 10.1161/CIRCULATIONAHA.113.008461.
134. Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, Fox J, Chakrabarti S, Sauer AJ, Rich JD, Freed BH, Shah SJ, Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2014 7 288 299. doi: 10.1161/CIRCHEARTFAILURE.113.000854.
135. Guazzi M, Vicenzi M, Arena R, Guazzi MD, Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011 124 164 174. doi: 10.1161/CIRCULATIONAHA.110.983866.
136. Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, Borlaug BA, Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail 2015 8 542 550. doi: 10.1161/CIRCHEARTFAILURE.114.002114.
137. Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, Bojic A, Lam CS, Frey R, Ochan Kilama M, Unger S, Roessig L, Lang IM, Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014 146 1274 1285. doi: 10.1378/chest.14-0106.
138. Zile MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC, Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail 2014 2 123 130. doi: 10.1016/j.jchf.2013.12.002.
139. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS, Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011 124 24 30. doi: 10.1161/CIRCULATIONAHA.110.979203.
140. Melenovsky V, Andersen MJ, Andress K, Reddy YN, Borlaug BA, Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications. Eur J Heart Fail 2015 17 1161 1171. doi: 10.1002/ejhf.417.
141. Olson TP, Johnson BD, Borlaug BA, Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016 4 490 498
142. Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW, Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol 2014 113 1211 1216. doi: 10.1016/j.amjcard.2013.12.031.
143. Heinonen I, Bucci M, Kemppainen J, Knuuti J, Nuutila P, Boushel R, Kalliokoski KK, Regulation of subcutaneous adipose tissue blood flow during exercise in humans. J Appl Physiol (1985) 2012 112 1059 1063. doi: 10.1152/japplphysiol.00732.2011.
144. Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, Haykowsky M, Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 2014 306 H1364 H1370. doi: 10.1152/ajpheart.00004.2014.
145. Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD, Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 2011 13 1296 1304. doi: 10.1093/eurjhf/hfr133.
146. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A, Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012 59 998 1005. doi: 10.1016/j.jacc.2011.11.040.
147. Kitzman DW, Haykowsky MJ, Mechanisms of exercise training in heart failure with preserved ejection fraction: central disappointment and peripheral promise. Am Heart J 2012 164 807 809
148. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC, Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010 3 659 667. doi: 10.1161/CIRCHEARTFAILURE.110.958785.
149. Edelmann F, Gelbrich G, Düngen HD, Fröhling S, Wachter R, Stahrenberg R, Binder L, Töpper A, Lashki DJ, Schwarz S, Herrmann-Lingen C, Löffler M, Hasenfuss G, Halle M, Pieske B, Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011 58 1780 1791. doi: 10.1016/j.jacc.2011.06.054.
150. Fujimoto N, Prasad A, Hastings JL, Bhella PS, Shibata S, Palmer D, Levine BD, Cardiovascular effects of 1 year of progressive endurance exercise training in patients with heart failure with preserved ejection fraction. Am Heart J 2012 164 869 877. doi: 10.1016/j.ahj.2012.06.028.
151. Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J, Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 2015 17 925 935. doi: 10.1002/ejhf.327.
152. Melenovsky V, Hwang SJ, Redfield MM, Zakeri R, Lin G, Borlaug BA, Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 2015 8 295 303. doi: 10.1161/CIRCHEARTFAILURE.114.001667.
153. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016 133 484 492. doi: 10.1161/CIRCULATIONAHA.115.018614.
154. Elliott AD, Mahajan R, Pathak RK, Lau DH, Sanders P, Exercise training and atrial fibrillation: further evidence for the importance of lifestyle change. Circulation 2016 133 457 459. doi: 10.1161/CIRCULATIONAHA.115.020800.
155. Machino-Ohtsuka T, Seo Y, Ishizu T, Sugano A, Atsumi A, Yamamoto M, Kawamura R, Machino T, Kuroki K, Yamasaki H, Igarashi M, Sekiguchi Y, Aonuma K, Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2013 62 1857 1865. doi: 10.1016/j.jacc.2013.07.020.